CPVI Plus Renal Sympathetic Modification Versus CPVI Alone for AF（Atrial Fibrillation） Ablation
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01686542|
Recruitment Status : Recruiting
First Posted : September 18, 2012
Last Update Posted : July 17, 2017
|Condition or disease||Intervention/treatment|
|Atrial Fibrillation||Procedure: CPVI plus renal sympathetic modification Procedure: CPVI|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||100 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Circumferential Pulmonary Vein Isolation (CPVI) Plus Renal Sympathetic Modification Versus CPVI Alone for AF Ablation: a Pilot Study|
|Actual Study Start Date :||June 2012|
|Estimated Primary Completion Date :||June 2019|
|Estimated Study Completion Date :||June 2020|
Experimental: CPVI+RSM group
Circumferential pulmonary vein isolation (CPVI) plus renal sympathetic modification for atrial fibrillation ablation.
Procedure: CPVI plus renal sympathetic modification
CPVI plus renal denervation to reduce atrial arrhythmia recurrence.
Active Comparator: CPVI group
Circumferential pulmonary vein isolation is done alone for atrial fibrillation.
CPVI alone to reduce atrial arrhythmia recurrence.
Other Name: circumferential pulmonary vein ablation
- The relapse rate of atrial tachyarrhythmia [ Time Frame: Four years ]Atrial tachyarrhythmia lasting more than 30 seconds consider relapsed
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01686542
|Contact: Yuehui Yin, MDemail@example.com|
|Chongqing, Chongqing, China, 400010|
|Contact: Yuehui Yin, MD 0086-23-63693766 firstname.lastname@example.org|
|Principal Investigator: Yuehui Yin, MD|